<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02749968</url>
  </required_header>
  <id_info>
    <org_study_id>Droege 2016</org_study_id>
    <nct_id>NCT02749968</nct_id>
  </id_info>
  <brief_title>Intercostal Liposomal Bupivacaine for the Management of Blunt Chest Wall Trauma</brief_title>
  <official_title>Intercostal Liposomal Bupivacaine for the Management of Blunt Chest Wall Trauma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Air Force</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Cincinnati</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study of liposomal bupivacaine for pain control in patients with blunt chest wall
      trauma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate the efficacy of liposomal bupivacaine to provide
      analgesia via paravertebral intercostal nerve block following significant blunt chest trauma,
      minimizing adverse outcomes, length of stay and overall narcotic use. The primary outcome of
      the study is to compare requirements between the bupivacaine group and a standard-of-care
      group.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 9, 2018</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">February 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Opioid requirement at 6 hours post-randomization</measure>
    <time_frame>6 hours following randomization.</time_frame>
    <description>Opioid requirement (in morphine equivalents) at 6 hours post-randomization</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Opioid requirement at 12 hours post-randomization</measure>
    <time_frame>12 hours following randomization.</time_frame>
    <description>Opioid requirement (in morphine equivalents) at 12 hours post-randomization</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Opioid requirement at 18 hours post-randomization</measure>
    <time_frame>18 hours following randomization.</time_frame>
    <description>Opioid requirement (in morphine equivalents) at 18 hours post-randomization</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Opioid requirement at 24 hours post-randomization</measure>
    <time_frame>24 hours following randomization.</time_frame>
    <description>Opioid requirement (in morphine equivalents) at 24 hours post-randomization</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Opioid requirement at 30 hours post-randomization</measure>
    <time_frame>30 hours following randomization.</time_frame>
    <description>Opioid requirement (in morphine equivalents) at 30 hours post-randomization</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Opioid requirement at 36 hours post-randomization</measure>
    <time_frame>36 hours following randomization.</time_frame>
    <description>Opioid requirement (in morphine equivalents) at 36 hours post-randomization</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Opioid requirement at 42 hours post-randomization</measure>
    <time_frame>42 hours following randomization.</time_frame>
    <description>Opioid requirement (in morphine equivalents) at 42 hours post-randomization</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Opioid requirement at 48 hours post-randomization.</measure>
    <time_frame>48 hours following randomization.</time_frame>
    <description>Opioid requirement (in morphine equivalents) at 48 hours post-randomization</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Opioid requirement at 54 hours post-randomization</measure>
    <time_frame>54 hours following randomization.</time_frame>
    <description>Opioid requirement (in morphine equivalents) at 54 hours post-randomization</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Opioid requirement at 60 hours post-randomization</measure>
    <time_frame>60 hours following randomization.</time_frame>
    <description>Opioid requirement (in morphine equivalents) at 60 hours post-randomization</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Opioid requirement at 66 hours post-randomization</measure>
    <time_frame>66 hours following randomization.</time_frame>
    <description>Opioid requirement (in morphine equivalents) at 66 hours post-randomization</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Opioid requirement at 72 hours post-randomization</measure>
    <time_frame>72 hours following randomization.</time_frame>
    <description>Opioid requirement (in morphine equivalents) at 72 hours post-randomization</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Opioid requirement at 78 hours post-randomization</measure>
    <time_frame>78 hours following randomization.</time_frame>
    <description>Opioid requirement (in morphine equivalents) at 78 hours post-randomization</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Opioid requirement at 84 hours post-randomization</measure>
    <time_frame>84 hours following randomization.</time_frame>
    <description>Opioid requirement (in morphine equivalents) at 84 hours post-randomization</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Opioid requirement at 90 hours post-randomization</measure>
    <time_frame>90 hours following randomization.</time_frame>
    <description>Opioid requirement (in morphine equivalents) at 90 hours post-randomization</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Opioid requirement at 96 hours post-randomization</measure>
    <time_frame>96 hours following randomization.</time_frame>
    <description>Opioid requirement (in morphine equivalents) at 96 hours post-randomization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Development of pneumonia</measure>
    <time_frame>96 hours following randomization</time_frame>
    <description>Development of pneumonia defined as &gt;100,000 cfu/mL bacteria on bronchoalveolar lavage or clinically with leukocytosis, pulmonary infiltrate and fever with 96 hours post-randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-reported pain every 6 hours post-randomization</measure>
    <time_frame>Every 6 hours from randomization until 96 hours post-randomization</time_frame>
    <description>Self-reported pain will be measured using the verbal NRS, a 0-10 ordinal scale. Pain assessments will occur every 6 hours or per standard of care for the appropriate setting (e.g., intensive care unit, trauma ward) for the first 96 hours of hospital stay.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Blunt Chest Wall Trauma</condition>
  <condition>Rib Fracture</condition>
  <condition>Sternal Fracture</condition>
  <arm_group>
    <arm_group_label>Liposomal bupivacaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 mL of liposomal bupivacaine injected with a 25-G needle just below each affected rib by the intercostal neurovascular bundle in a paraspinal position</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.9% sodium chloride</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 mL of 0.9% saline injected with a 25-G needle just below each affected rib by the intercostal neurovascular bundle in a paraspinal position</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposomal bupivacaine</intervention_name>
    <description>1 mL of liposomal bupivacaine injected with a 25-G needle just below each affected rib by the intercostal neurovascular bundle in a paraspinal position</description>
    <arm_group_label>Liposomal bupivacaine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.9% sodium chloride</intervention_name>
    <description>1 mL of 0.9% saline injected with a 25-G needle just below each affected rib by the intercostal neurovascular bundle in a paraspinal position</description>
    <arm_group_label>0.9% sodium chloride</arm_group_label>
    <other_name>0.9% saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Anticipated length of stay of at least 72 hours

          -  Blunt chest wall trauma with two or more rib or sternal fractures

          -  Demonstrated ability to achieve &gt; 50% predicted inspiratory capacity based on ideal
             body weight using IS within the first 24 hours of admission

        Exclusion Criteria:

          -  Known allergy to bupivacaine

          -  Respiratory failure requiring intubation within 24 hours prior to enrollment

          -  Known or suspected atrioventricular nodal blockade process requiring cardiology
             evaluation or pacemaker placement

          -  Hemodynamic instability (defined as new intravenous vasopressor or inotrope
             requirement or mean arterial pressure &lt; 55 mmHg)

          -  Signs of active myocardial ischemia or non-ST elevation MI

          -  &gt; 20 rib fractures

          -  Weight &lt; 50 kg or &gt; 150 kg

          -  Pregnancy

          -  Incarceration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael D Goodman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Surgery, University of Cincinnati</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christopher Droege, PharmD</last_name>
    <phone>513-584-8053</phone>
    <email>droegeca@ucmail.uc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michael D Goodman, MD</last_name>
    <phone>513-558-5661</phone>
    <email>goodmamd@ucmail.uc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Cincinnati Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Molly Droege, PharmD</last_name>
      <phone>513-584-2126</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 18, 2016</study_first_submitted>
  <study_first_submitted_qc>April 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2016</study_first_posted>
  <last_update_submitted>May 1, 2018</last_update_submitted>
  <last_update_submitted_qc>May 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cincinnati</investigator_affiliation>
    <investigator_full_name>Michael Goodman</investigator_full_name>
    <investigator_title>instructor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fractures, Bone</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Rib Fractures</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

